Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 6(106), p. 1153-1159, 2012

DOI: 10.1038/bjc.2012.50

Links

Tools

Export citation

Search in Google Scholar

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.

Journal article published in 2012 by Rj J. Young, Tin Aw, A. W. Tin, Nj J. Brown, M. Jitlal, Sm M. Lee, Pj J. Woll ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Thalidomide has potent anti-inflammatory and anti-angiogenic properties. It was evaluated in combination with chemotherapy in two randomised placebo-controlled trials in patients with small cell lung cancer (SCLC, n=724) and advanced non-small cell lung cancer (NSCLC, n=722). Neither study demonstrated an improvement in overall survival with the addition of thalidomide to chemotherapy. This study investigated circulating angiogenic biomarkers in a subset of these patients.